In addition, the antibody blockade of CXCR2 signaling reduces the expression levels of tissue IL-23 in the liver and intestine at the initial stage of graft-versus-host disease (GVHD) and attenuates disease severity (17). This evidence concerns the gene IL23A and graft versus host disease.